137 related articles for article (PubMed ID: 3264755)
1. Increase of striatal dopamine turnover by stress in MPTP-treated mice.
Urakami K; Masaki N; Shimoda K; Nishikawa S; Takahashi K
Clin Neuropharmacol; 1988 Aug; 11(4):360-8. PubMed ID: 3264755
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
3. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
[TBL] [Abstract][Full Text] [Related]
4. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Muthian G; Mackey V; King J; Charlton CG
Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
[TBL] [Abstract][Full Text] [Related]
5. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
6. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
Sirinathsinghji DJ; Heavens RP; McBride CS
Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
[TBL] [Abstract][Full Text] [Related]
7. Increased striatal dopamine turnover following acute administration of rotenone to mice.
Thiffault C; Langston JW; Di Monte DA
Brain Res; 2000 Dec; 885(2):283-8. PubMed ID: 11102582
[TBL] [Abstract][Full Text] [Related]
8. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen JN; Sobotka TJ; Weise VK; Markey SP
J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Boireau A; Bordier F; Dubédat P; Pény C; Impérato A
Neurosci Lett; 1997 Oct; 234(2-3):123-6. PubMed ID: 9364513
[TBL] [Abstract][Full Text] [Related]
10. Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice.
Khan HA
Neurochem Int; 2010 Nov; 57(5):489-91. PubMed ID: 20619308
[TBL] [Abstract][Full Text] [Related]
11. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
12. Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
Prell GD; Khandelwal JK; Burns RS; Blandina P; Morrishow AM; Green JP
J Neural Transm Park Dis Dement Sect; 1991; 3(2):109-25. PubMed ID: 1910485
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Sershen H; Hashim A; Lajtha A
Pharmacol Biochem Behav; 1987 Oct; 28(2):299-303. PubMed ID: 3500479
[TBL] [Abstract][Full Text] [Related]
14. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.
Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD
Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420
[TBL] [Abstract][Full Text] [Related]
15. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse.
Ferraro TN; Golden GT; DeMattei M; Hare TA; Fariello RG
Neuropharmacology; 1986 Sep; 25(9):1071-4. PubMed ID: 2430229
[TBL] [Abstract][Full Text] [Related]
17. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
Hadjiconstantinou M; Neff NH
J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149
[TBL] [Abstract][Full Text] [Related]
18. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.
Tabatabaei A; Perry TL; Hansen S; Krieger C
Neurosci Lett; 1992 Jul; 141(2):192-4. PubMed ID: 1436633
[TBL] [Abstract][Full Text] [Related]
19. Sodium diethyldithiocarbamate protects against the MPTP-induced inhibition of immune responses in mice.
Renoux G; Bizière K; Renoux M; Steinberg R; Kan JP; Guillaumin JM
Life Sci; 1989; 44(12):771-7. PubMed ID: 2539542
[TBL] [Abstract][Full Text] [Related]
20. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Fazzini E; Durso R; Davoudi H; Szabo GK; Albert ML
J Neurol Sci; 1990 Oct; 99(1):59-68. PubMed ID: 2250172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
